This article first appeared on GuruFocus.
Release Date: March 19, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
DocMorris AG (XSWX:DOCM) achieved a revenue growth of 11.1% and met its financial targets for 2025.
The company’s digital services segment experienced a remarkable growth rate of 110%, contributing significantly to profitability.
The AI Health Companion, launched as a beta version, has been rapidly adopted, with every third app user utilizing the assistant.
DocMorris AG (XSWX:DOCM) maintains a strong liquidity position with CHF160 million, providing confidence for future execution.
The company has formed a strategic partnership with Google to leverage AI capabilities, enhancing its digital healthcare platform.
The segment EU showed modest growth and remains slightly EBITDA negative due to low growth and indirect cost base.
Distribution expenses increased due to higher logistics and transport costs, impacting overall profitability.
The net financial result showed a negative impact of 12 million, primarily due to non-cash effects related to intercompany loans.
The company faces challenges in achieving EBITDA break-even in 2026 and free cash flow break-even in 2027.
There is uncertainty in the RX growth outlook, which is a primary swing factor in the company’s guidance range.
Q: What is the primary swing factor within your sales outlook for this year? Is it mainly driven by uncertainty around RX growth or OTC performance? A: The main factor is definitely RX. We are playing operating profit against growth, and the co-payment and bonus developments are significant swing factors. OTC BPC is expected to grow mid-single-digit, and digital services are projected to grow mid-double-digit. The volatility mainly lies with RX growth.
Q: Regarding your midterm growth targets of 15%, how do you plan to achieve this given the OTC part is growing at mid-single-digit? A: You are correct that RX growth needs to be higher than 20% to achieve the 15% target. We expect RX growth to be around 20% initially, with substantial growth expected from 2028 to 2030. This will be supported by increased marketing efficiency and platform dynamics.
Q: What is the current market share of online pharmacies in Germany, and what growth do you expect in the next few years? A: The market share of online pharmacies was 1.35% six years ago, dropped to 0.75%, and has now increased to roughly 1.7% with the introduction of ERX. We conservatively estimate a market share of 5-6% in five years, although it could ramp up faster.
